Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab for Schnitzler syndrome
NL-OMON34354Phase 2Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Dec 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of canakinumab in Schnitzler syndrome, sponsored by Radboud University Medical Center. Primary endpoint: Primary efficacy endpoint. Started Dec 2010; status: recruiting.
02
Drugs
canakinumab
03
Conditions
Schnitzler syndrome
Beyond the preview
Go deeper on NL-OMON34354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34354.